Normal view MARC view ISBD view

Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. [Review]

MedStar author(s):

Citation: Clinical lymphoma, myeloma & leukemia. 22(5):e285-e292, 2022 05.PMID: 34879994Department: MedStar Health Baltimore ResidentsForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Antineoplastic Agents | *Immunoglobulin Light-chain Amyloidosis | Antibodies, Monoclonal/ae [Adverse Effects] | Antineoplastic Agents/tu [Therapeutic Use] | Humans | Immunoglobulin Light-chain Amyloidosis/di [Diagnosis] | Immunoglobulin Light-chain Amyloidosis/dt [Drug Therapy] | Neoplasm Recurrence, Local/dt [Drug Therapy] | Treatment OutcomeYear: 2022 ISSN:

2152-2669

Name of journal: Clinical lymphoma, myeloma & leukemiaAbstract: With recent advances in novel chemotherapeutic agents and increasing use of autologous hematopoietic stem cell transplant, there has been a significant improvement in outcomes for patients with AL Amyloidosis. Daratumumab, with its excellent safety and efficacy profile, appears to be an ideal treatment option for patients with newly diagnosed as well as relapsed refractory AL amyloidosis. In this systematic review, we analyzed the published literature on the role of Daratumumab in pretreated relapsed and refractory AL-amyloidosis patients using PubMed, Embase, Cochrane, and clinicaltrials.gov databases. A total of 16 studies evaluated the role of Daratumumab as monotherapy (DMT) or in combination with other chemotherapeutic agents (DCT). DMT and DCT were associated with promising efficacy with hematologic and organ responses (cardiac/renal) seen in 50%-90% and 50%-80% of the patients, respectively. Daratumumab appeared to be well tolerated with no significant treatment-related adverse events as DMT or DCT. Copyright (c) 2021. Published by Elsevier Inc.All authors: Ansar I, Ehsan A, Ehsan H, Hashmi H, Masood A, Neupane K, Rafae A, Sana MK, Umar A, Wahab AOriginally published: Clinical lymphoma, myeloma & leukemia. 2021 Nov 01Fiscal year: FY2022 Digital Object Identifier:

https://dx.doi.org/10.1016/j.clml.2021.10.014

Date added to catalog: 2022-01-25

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	34879994	Available		34879994

With recent advances in novel chemotherapeutic agents and increasing use of autologous hematopoietic stem cell transplant, there has been a significant improvement in outcomes for patients with AL Amyloidosis. Daratumumab, with its excellent safety and efficacy profile, appears to be an ideal treatment option for patients with newly diagnosed as well as relapsed refractory AL amyloidosis. In this systematic review, we analyzed the published literature on the role of Daratumumab in pretreated relapsed and refractory AL-amyloidosis patients using PubMed, Embase, Cochrane, and clinicaltrials.gov databases. A total of 16 studies evaluated the role of Daratumumab as monotherapy (DMT) or in combination with other chemotherapeutic agents (DCT). DMT and DCT were associated with promising efficacy with hematologic and organ responses (cardiac/renal) seen in 50%-90% and 50%-80% of the patients, respectively. Daratumumab appeared to be well tolerated with no significant treatment-related adverse events as DMT or DCT. Copyright (c) 2021. Published by Elsevier Inc.

English